Smith & Nephew SNATS (SNN)
(Delayed Data from NYSE)
$25.13 USD
+0.45 (1.82%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $25.12 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$25.13 USD
+0.45 (1.82%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $25.12 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth D Momentum A VGM
Zacks News
Smith+Nephew's (SNN) New Device to Boost Patient Outcomes
by Zacks Equity Research
Smith+Nephew's (SNN) FAST-FLIX FLEX Meniscal Repair System to provide long-term benefits to patients.
The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic
Coronavirus Ups the Game for Robotic Surgery: 3 Stocks on Radar
by Sriparna Ghosal
Let's keep a watch on the potentially strong three MedTech stocks, namely SYK, ARAY and MDT with respect to robotic-assisted surgery that showed promises during the pandemic.
Smith+Nephew's (SNN) PICO sNPWT Study Outcome Encouraging
by Zacks Equity Research
Smith+Nephew's (SNN) PICO Single Use Negative Pressure Wound Therapy System (sNPWT) considerably reduces surgical site infections complications and provides better patient outcome.
Integra (IART) Sells Unprofitable Arm to Focus on Core Business
by Zacks Equity Research
Integra (IART) does not expect the selloff to have a material impact on its 2020 results.
Integra (IART) to Buy ACell, Expand Regenerative Capability
by Zacks Equity Research
Integra (IART) expects to close the ACell acquisition in the first quarter of 2021, subject to fulfilment of closing conditions.
Is Smith & Nephew (SNN) a Suitable Stock for Value Investors?
by Zacks Equity Research
Let's see if Smith & Nephew plc (SNN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Robot-Assisted Surgery Gains Momentum Amid Coronavirus
by Trina Mukherjee
Let's keep a watch on potentially strong three MedTech stocks with respect to robotic-assisted surgery that have shown promise during the pandemic.
Smith+Nephew Unveils Digital Platform to Boost Patient Care
by Zacks Equity Research
With the help of the care management platform, Smith+Nephew (SNN) aims to help clinicians reduce the patient's post-acute recovery time.
Abbott (ABT) Q4 Earnings Match Estimates, Revenues Beat Mark
by Zacks Equity Research
We are upbeat about Abbott's (ABT) strong and consistent EPD and Medical Devices performances, organically.
Smith & Nephew's JOURNEY II UK Knee System Executes Surgeries
by Zacks Equity Research
The JOURNEY II UK development is expected to provide a major impetus to Smith & Nephew's (SNN) Orthopedics segment.
Smith & Nephew's Study Outcomes for REGENETEN Encouraging
by Zacks Equity Research
Smith & Nephew's (SNN) announces positive study outcomes for REGENETEN.
Smith & Nephew's (SNN) STITCH Study Outcome Encouraging
by Zacks Equity Research
This can be considered a major step in Smith & Nephew's (SNN) commitment toward strengthening its Global Sports Medicine and ENT segment.
Smith & Nephew (SNN) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Smith & Nephew (SNN) has been gaining from several positive developments of late.
Smith & Nephew Acquires Atracsys, Expands Robotic Portfolio
by Zacks Equity Research
With Smith & Nephew's (SNN) buyout of Atracsys, the latter's fusionTrack 500 optical tracking camera will be a core enabling technology for the company's next-generation robotics platform.
Smith & Nephew (SNN) Buys Brainlab, Braces Robotic Ecosystem
by Zacks Equity Research
The transaction by Smith & Nephew (SNN), besides the business purchase, comprises certain intangible assets and the orthopaedic Brainlab salesforce.
Titan Medical (TMDI) Shows Promise on Strategic Developments
by Zacks Equity Research
Titan Medical (TMDI) is putting in a good deal of effort to strengthen its position in the multi-billion dollar computer-assisted robotic surgical technologies market.
Here's Why You Should Invest in Smith & Nephew (SNN) Now
by Zacks Equity Research
Smith & Nephew (SNN) has been gaining investor confidence on consistently positive results.
Here's Why You Should Invest in Baxter International Now
by Zacks Equity Research
Baxter (BAX) teams up with bioMerieux to treat acute kidney injury.
The Zacks Analyst Blog Highlights: Rio Tinto, Smith & Nephew, Endava, AstraZeneca and British American Tobacco
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Rio Tinto, Smith & Nephew, Endava, AstraZeneca and British American Tobacco
Is Britain Headed for a Soft Brexit? 5 Picks
by Swarup Gupta
Following May's fresh legislative defeat, Britain could exit the EU while retaining access to its common market.
Smith & Nephew (SNN): Moving Average Crossover Alert
by Zacks Equity Research
Smith & Nephew plc (SNN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Orthopedic Device Market Gains Momentum: 3 Stocks in Focus
by Zacks Equity Research
The orthopedics market holds immense potential for investors who are keen on the healthcare space for long-term gains.
Medical Device Industry Outlook - February 2018
by Zacks Equity Research
Amid the concerns related to the tax reform, Congress' postponement of the medical device tax for another two years came as a huge relief to industry participants and investors.
MedTech Tax Resumes in 2018, 3 Stocks to Suffer
by Zacks Equity Research
Sectors that are likely to be hampered the most by the re-imposition of the medical device tax are X-ray and MRI machines, surgical instruments and pacemakers.